VFA
ALNY icon

Values First Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Values First Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Sell
3,178
-68
-2% -$20.5K 0.44% 67
2026
Q1 		$1.07M Buy
3,246
+20
+0.6% +$6.81K 0.56% 55
2025
Q4 		$1.28M Sell
3,226
-656
-17% -$290K 0.67% 48
2025
Q3 		$1.77M Sell
3,882
-65
-2% -$26.5K 0.95% 40
2025
Q2 		$1.29M Sell
3,947
-4,166
-51% -$1.15M 0.7% 48
2025
Q1 		$2.19M Sell
8,113
-879
-10% -$226K 1.28% 16
2024
Q4 		$2.12M Buy
8,992
+202
+2% +$53.1K 1.16% 17
2024
Q3 		$2.42M Buy
8,790
+1,200
+16% +$312K 1.31% 15
2024
Q2 		$1.84M Sell
7,590
-148
-2% -$23.4K 1.11% 31
2024
Q1 		$1.16M Buy
7,738
+755
+11% +$126K 0.68% 45
2023
Q4 		$1.34M Buy
6,983
+476
+7% +$81.1K 0.81% 41
2023
Q3 		$1.15M Sell
6,507
-50
-0.8% -$9.54K 0.74% 42
2023
Q2 		$1.25M Buy
6,557
+146
+2% +$28.9K 0.75% 42
2023
Q1 		$1.28M Buy
6,411
+109
+2% +$22.9K 0.82% 35
2022
Q4 		$1.5M Buy
6,302
+35
+0.6% +$7.46K 1.05% 30
2022
Q3 		$1.25M Buy
6,267
+201
+3% +$38.3K 0.9% 35
2022
Q2 		$885K Sell
6,066
-430
-7% -$61K 0.63% 52
2022
Q1 		$1.06M Buy
6,496
+347
+6% +$52.9K 0.67% 49
2021
Q4 		$1.04M Sell
6,149
-368
-6% -$68.4K 0.62% 56
2021
Q3 		$1.23M Buy
6,517
+213
+3% +$40K 0.8% 43
2021
Q2 		$1.07M Sell
6,304
-130
-2% -$19K 0.73% 49
2021
Q1 		$908K Buy
6,434
+99
+2% +$14.9K 0.67% 52
2020
Q4 		$823K Sell
6,335
-199
-3% -$26.6K 0.66% 54
2020
Q3 		$951K Buy
6,534
+331
+5% +$47K 0.87% 45
2020
Q2 		$919K Sell
6,203
-146
-2% -$19.7K 0.91% 45
2020
Q1 		$691K Buy
6,349
+367
+6% +$42.4K 0.83% 45
2019
Q4 		$689K Buy
+5,982
New +$596K 0.67% 54

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Values First Advisors's ALNY Position: Q2 2026 in Review

Values First Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.1% in Q2 2026, selling an estimated $20.5K and leaving 3,178 shares worth $957K. The position accounts for 0.44% of the portfolio, ranked #67.

Values First Advisors first reported a position in ALNY in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.42M in Q3 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Values First Advisors held 3,178 shares of Alnylam Pharmaceuticals worth $957K as of Q2 2026.
  • Values First Advisors sold 68 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $20.5K.
  • Alnylam Pharmaceuticals made up 0.44% of Values First Advisors's portfolio in Q2 2026, its #67 holding.
  • Values First Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Values First Advisors's Alnylam Pharmaceuticals position peaked at $2.42M in Q3 2024.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Values First Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.